Depression is often described as persistent sadness, but for many people the illness goes much deeper than feeling unhappy. One of the most painful symptoms is the loss of motivation, enjoyment, and interest in life.
Activities that once brought happiness may suddenly feel empty. Hobbies become difficult to enjoy, social gatherings lose their appeal, and even simple daily tasks can feel exhausting. This symptom is known as anhedonia, and it is one of the most difficult aspects of depression to treat.
Now, researchers in Sweden have reported encouraging results from a study suggesting that a drug originally developed for Parkinson’s disease may help some people with treatment-resistant depression regain motivation and pleasure in life.
The research was conducted by scientists from Lund University and psychiatric specialists from Region Skåne and was published in the journal Nature Medicine.
Depression affects hundreds of millions of people worldwide. While many patients benefit from antidepressant medications, psychotherapy, or a combination of treatments, a significant number continue to struggle despite receiving appropriate care.
These individuals are often described as having treatment-resistant depression. For them, symptoms may persist for years and can greatly affect relationships, work, physical health, and overall quality of life.
One of the biggest challenges in treating depression is that current antidepressants often work better for reducing sadness and anxiety than they do for restoring pleasure and motivation.
Many patients report that although they feel less distressed, they still struggle to enjoy life. This has led researchers to search for treatments that specifically target anhedonia.
The Swedish research team focused on a drug called pramipexole. Doctors have used pramipexole for many years to treat Parkinson’s disease, a neurological condition that affects movement.
The medication works by influencing dopamine, a chemical messenger in the brain that plays a major role in reward, pleasure, motivation, and goal-directed behavior.
Scientists have long suspected that dopamine dysfunction may contribute to anhedonia in depression. If so, a medication that improves dopamine signaling might help restore the brain’s reward system. This idea led researchers to investigate whether pramipexole could help patients whose depression remained difficult to treat.
The study involved people with depression who showed particularly severe symptoms of anhedonia. Participants continued taking their usual antidepressant medications and were randomly assigned to receive either pramipexole or a placebo.
A placebo looks like the real medication but contains no active ingredient. Neither the participants nor the researchers knew who received which treatment until the study ended.
The treatment period lasted nine weeks. During that time, researchers carefully monitored symptoms, daily functioning, and possible side effects.
The results showed that patients receiving pramipexole experienced greater improvement in anhedonia compared with those taking the placebo. They reported increased interest in activities, improved motivation, and a greater ability to experience pleasure.
The benefits did not disappear when the study ended. Many participants chose to continue treatment, and researchers followed them for an additional six months. The improvements were largely maintained throughout this extended period, suggesting that the medication may provide lasting benefits for some patients.
To better understand why the treatment worked, researchers used advanced brain imaging technology known as 7-Tesla functional magnetic resonance imaging. This allowed them to examine activity within the brain’s reward system. They also used activity monitors to track movement and physical activity in daily life.
The findings suggested that pramipexole improved the functioning of brain circuits involved in reward and motivation. Participants receiving the medication also became more physically active, supporting the idea that the treatment was helping restore motivation and engagement with everyday life.
Most participants tolerated the medication well. Common side effects included nausea, dizziness, and sleep disturbances. In many cases, these problems improved when doctors adjusted the dosage. Few participants dropped out of the study because of side effects.
The researchers emphasized that careful monitoring remains important. Certain dopamine-related medications can sometimes affect impulse control, leading to behaviors such as excessive spending, gambling, or other compulsive activities. Daytime sleepiness may also occur in some patients.
The study is an example of drug repurposing, a strategy in which an existing medication is used for a different medical condition than it was originally designed to treat. Drug repurposing can sometimes speed up the development of new treatments because doctors already have extensive information about a medication’s safety profile.
The findings are particularly important because they address one of the most disabling aspects of depression. Many people can tolerate feeling sad less often, but they find the loss of enjoyment and purpose especially devastating. A treatment that restores these feelings could significantly improve quality of life.
From a scientific perspective, the study is promising because it used a randomized, placebo-controlled design and included biological evidence supporting the clinical improvements. However, the trial was relatively small, and additional studies involving larger groups of patients will be needed before pramipexole becomes a standard treatment for depression.
The findings suggest that targeting the brain’s dopamine system may be an effective strategy for treating anhedonia. If future research confirms these results, pramipexole could become an important new option for people whose depression has not responded well to existing therapies.
If you care about depression, please read studies about how dairy foods may influence depression risk, and B vitamins could help prevent depression and anxiety.
For more information about mental health, please see recent studies that ultra-processed foods may make you feel depressed, and extra-virgin olive oil could reduce depression symptoms.
Source: Lund University.
